64 Among participants treated with semaglutide, MASH resolution was achieved in 34% and fibrosis improvement was observed in 11%, though the latter did not reach statistical significance vs. placebo ( Table 1 ). 64 In addition to semi-quantitative histological scoring by the pathologist, neither automated collagen quantification nor liver stiffness measurements showed significant improvement with semaglutide compared with placebo, supporting the conclusion that in patients with cirrhosis, despite weight loss and MASH resolution, a 1-year treatment duration does not confer fibrosis benefit.
1
—
—